Role of Glucocorticoid Receptor in the Regulation of Cellular Sensitivity to Irinotecan hydrochloride (cas 100286-90-6)
-
Add time:07/26/2019 Source:sciencedirect.com
In clinical practice, glucocorticoids are often used with the aim of modulating the efficacy and toxicity of chemotherapeutic agents. However, how glucocorticoids modulate the pharmacological action of chemotherapeutic agents remains to be clarified. In this study, we generated glucocorticoid receptor (GR)-deficient rat-1 cells to investigate the role of GR in the regulation of cellular sensitivity to irinotecan hydrochloride (CPT-11). Treatment of wild-type rat-1 cells with dexamethasone (DEX) significantly enhanced the cytotoxic effect of CPT-11, whereas the treatment had little effect on the cytotoxicity of CPT-11 in GR-deficient cells. Topoisomerase-I activity in wild-type cells after concomitant treatment with DEX and CPT-11 was significantly lower than that after treatment with CPT-11 alone. DEX treatment also enhanced the inhibitory action of CPT-11 on the phosphatidylinositol 3-kinase–Akt signaling pathway in wild-type cells, accompanied by facilitating caspase-3 activity. These modulatory effects of DEX on the CPT-11–induced cytotoxicity were not observed in GR-deficient cells. Our present findings reveal the underlying mechanism by which GCs enhance the chemotherapeutic effect of CPT-11 and indicate the possibility that the dosage of CPT-11 could be reduced by the combination treatment with GCs, which may attenuate the adverse effect without decreasing anti-tumor activity.[Supplementary Figures: available only at http://dx.doi.org/10.1254/jphs.08219FP]
We also recommend Trading Suppliers and Manufacturers of Irinotecan hydrochloride (cas 100286-90-6). Pls Click Website Link as below: cas 100286-90-6 suppliers
Prev:Salvage chemotherapy with a combination of Irinotecan hydrochloride (cas 100286-90-6) and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study
Next:Effect of Fe-Mo promoters on HZSM-5 zeolite catalyst for 1-hexene aromatization) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Salvage chemotherapy with a combination of Irinotecan hydrochloride (cas 100286-90-6) and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study07/25/2019
- Halloysite nanotubes as carriers for irinotecan: Synthesis and characterization by experimental and molecular simulation methods07/24/2019
- Voltammetric behaviour of the anticancer drug irinotecan and its metabolites in acetonitrile. Implications for electrochemical therapeutic drug monitoring07/23/2019
- Clinical effects of Irinotecan hydrochloride (cas 100286-90-6) in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer07/22/2019
- Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats07/20/2019
- Impact of diet on irinotecan toxicity in mice07/21/2019
- Active loading liposomal Irinotecan hydrochloride (cas 100286-90-6): Preparation, in vitro and in vivo evaluation07/19/2019
- Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride (cas 100286-90-6) in rat plasma by using high performance liquid chromatography-diode array detector07/18/2019
- A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of Irinotecan hydrochloride (cas 100286-90-6) liposome injection07/17/2019
-
Health and Chemical more >


